In 2025, CrazyBulk is redefining building muscle after 50 by boosting healthy testosterone levels, improving mTOR ...

A supplement succeeds when it fits your life. PhenQ is meant to be simple: one capsule with breakfast, one with lunch.

Revenue for the second quarter of 2025 was $7.7 million, a decrease of 9% vs. the second quarter of 2024. Global recurring revenue of $5.1 million declined 4% YoY and equipment revenue of $2.5 million ...

Founded in 1988 in Istanbul, Turkey, Erdem Hospital is a multidisciplinary medical network specializing in advanced surgical ...

(Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric ...

In June, the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on ...

Total revenues were $15.3 million for the second quarter of 2025 compared to $8.0 million in the second quarter of 2024. The increase was primarily due to variability in customers’ manufacturing ...

Tenax remains on track to initiate a second registrational Phase 3 study of TNX-103, LEVEL-2, in patients with PH-HFpEF this year. The protocol for LEVEL-2 has been finalized, and the study will have ...

Revenues for the second quarter of 2025 were $2.7 million, increasing 26% compared to the first quarter of 2025. Hyperfine, Inc. sold 8 commercial Swoop® systems in the second quarter of 2025, up from ...

In July 2025, the FDA approved Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for pediatric dilated cardiomyopathy (DCM). The ...

Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. company to implement DeFi strategies on Hyperliquid blockchain Accumulates ...

Pending a partnership or other funding, Vaxart expects to conduct a Phase 2b safety and immunogenicity study that could potentially begin as early as the second half of 2025, followed by an End of ...